179 related articles for article (PubMed ID: 30464209)
1. Biological activity of Pt
Alonso-de Castro S; Terenzi A; Hager S; Englinger B; Faraone A; Martínez JC; Galanski MS; Keppler BK; Berger W; Salassa L
Sci Rep; 2018 Nov; 8(1):17198. PubMed ID: 30464209
[TBL] [Abstract][Full Text] [Related]
2. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
3. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
[TBL] [Abstract][Full Text] [Related]
4. Toward supramolecular nanozymes for the photocatalytic activation of Pt(IV) anticancer prodrugs.
Mazzei LF; Martínez Á; Trevisan L; Rosa-Gastaldo D; Cortajarena AL; Mancin F; Salassa L
Chem Commun (Camb); 2020 Sep; 56(72):10461-10464. PubMed ID: 32910125
[TBL] [Abstract][Full Text] [Related]
5. Unexpected photoactivation pathways in a folate-receptor-targeted
Gandioso A; Rovira A; Shi H; Sadler PJ; Marchán V
Dalton Trans; 2020 Sep; 49(34):11828-11834. PubMed ID: 32815971
[TBL] [Abstract][Full Text] [Related]
6. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
7. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
8. Engineered flavoproteins as bioorthogonal photo-triggers for the activation of metal-based anticancer prodrugs.
Mazzei LF; Gurruchaga-Pereda J; Martínez Á; Martínez JC; Salassa L; Cortajarena AL
Chem Commun (Camb); 2023 Apr; 59(32):4754-4757. PubMed ID: 36974961
[TBL] [Abstract][Full Text] [Related]
9. Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light.
Kratochwil NA; Bednarski PJ; Mrozek H; Vogler A; Nagle JK
Anticancer Drug Des; 1996 Mar; 11(2):155-71. PubMed ID: 8630187
[TBL] [Abstract][Full Text] [Related]
10. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
11. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
Shi H; Romero-Canelón I; Hreusova M; Novakova O; Venkatesh V; Habtemariam A; Clarkson GJ; Song JI; Brabec V; Sadler PJ
Inorg Chem; 2018 Nov; 57(22):14409-14420. PubMed ID: 30365308
[TBL] [Abstract][Full Text] [Related]
12. An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs.
Deng Z; Li C; Chen S; Zhou Q; Xu Z; Wang Z; Yao H; Hirao H; Zhu G
Chem Sci; 2021 Apr; 12(19):6536-6542. PubMed ID: 34040729
[TBL] [Abstract][Full Text] [Related]
13. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging.
Li X; Mu J; Liu F; Tan EW; Khezri B; Webster RD; Yeow EK; Xing B
Bioconjug Chem; 2015 May; 26(5):955-61. PubMed ID: 25938732
[TBL] [Abstract][Full Text] [Related]
14. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
Almotairy ARZ; Gandin V; Morrison L; Marzano C; Montagner D; Erxleben A
J Inorg Biochem; 2017 Dec; 177():1-7. PubMed ID: 28918353
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
Dabbish E; Ponte F; Russo N; Sicilia E
Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.
Spector D; Pavlov K; Beloglazkina E; Krasnovskaya O
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498837
[TBL] [Abstract][Full Text] [Related]
17.
Yuan S; Zhu Y; Dai Y; Wang Y; Jin D; Liu M; Tang L; Arnesano F; Natile G; Liu Y
Angew Chem Int Ed Engl; 2022 Jan; 61(4):e202114250. PubMed ID: 34800083
[TBL] [Abstract][Full Text] [Related]
18. Near infrared activation of an anticancer Pt(IV) complex by Tm-doped upconversion nanoparticles.
Ruggiero E; Hernández-Gil J; Mareque-Rivas JC; Salassa L
Chem Commun (Camb); 2015 Feb; 51(11):2091-4. PubMed ID: 25536114
[TBL] [Abstract][Full Text] [Related]
19. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
20. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
